EDIT Stock Analysis: Buy, Sell, or Hold?
EDIT - Editas Medicine, Inc. Common Stock
$3.11
0.17 (5.78%)
▲
5d:
+10.28%
30d:
+13.92%
90d:
+16.48%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 11, 2026
0d
Get Alerted When EDIT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: EDIT shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: EDIT shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: EDIT is currently trading at $3.11, which is considered extended relative to its 30-day fair value range of $2.68 to $3.02.
Technical Outlook: Technically, EDIT is in a strong uptrend. Immediate support is located at $2.71, while resistance sits at $3.30. The stock is showing strong short-term momentum, up 5.8% recently.
Market Sentiment: EDIT scores 13/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.00 (+104.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, EDIT is in a strong uptrend. Immediate support is located at $2.71, while resistance sits at $3.30. The stock is showing strong short-term momentum, up 5.8% recently.
Market Sentiment: EDIT scores 13/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $6.00 (+104.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$2.68 -
$3.02
Company Quality Score
41/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
31.6%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (13/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+5.8%)
- BULLISH: Trading 104.1% below Wall St target ($6.00)
- WARNING: Composite score 41/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$2.68 -
$3.02
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$2.72
Resistance Level
$3.30
Current Trend
Strong Uptrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.90
Wall Street Target
$6.00
(+104.1%)
Revenue Growth (YoY)
232.3%
Profit Margin
-157.3%
Share & Embed Analysis
Last updated: August 21, 2026 4:15 PM ET
Data refreshes hourly during market hours. Next update: 5:15 PM
Data refreshes hourly during market hours. Next update: 5:15 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is EDIT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Amy Parison
SELL
474 shares
2026-03-03
Gilmore Neil O'neill
SELL
5394 shares
2026-03-03
Linda Burkly
SELL
749 shares
2026-03-03
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 42 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 66 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$108 | 52 HOLD |
|
BNTX
BioNTech SE |
STRONG BUY
21 analysts |
$121 | 41 HOLD |
